WASHINGTON…A panel of advisers to the Food and Drug Administration voted 6-0 to halt the use of cancer drug Avastin for the treatment of breast cancer, saying studies have failed to show Avastin is effective for that purpose.
The recommendation Wednesday came after two days of testimony from patients, doctors, and advocacy groups. The panel faced several tearful accounts, like that of Crystal Hanna, a mother of two who will celebrate her 36th birthday Friday. "I'm a testament that the drug does work…I'm not just a statistic," she said. "Keep breast cancer on the label so that I and others like me can celebrate more birthdays."
Advisers acknowledged the emotional nature of the issue, but said the science should prevail. "I think we all wanted Avastin to succeed," said Natalie Compagni-Portis, a member of the committee. "And yet what we have to do today is respond to the research that's been presented to us…these studies didn't bear out that hope."
The drug will remain on the market for other cancer treatments, but the FDA's withdrawal will likely mean insurance companies won't cover it for breast cancer patients. As a result, many women won't be able to afford the treatments, which can cost up to $100,000 a year.